PTN Gears up to Present at the 2016 Pediatric Academic Society (PAS) Meeting

PTN Investigators to present abstracts at the PAS Meeting in Baltimore, April 30-May 3

Here’s a sampling of presentations with more to come:

  • Platform Presentation: Sunday, May 1 at 4:15 PM–Dosing of antimicrobials in the neonatal in the NICU: Does clinical practice reflect published recommendations? M England, RG Greenberg, RH Clark, M Laughon, M Cohen-Wolkowiez, DK Benjamin Jr, and PB Smith on behalf of the Administrative Core Committee of the Best Pharmaceuticals for Children Act – Pediatric Trials Network.
  • Platform Presentation: Saturday, April 30, 2016 at 8:00 AM–Use of Pediatric and Adult Midazolam Population Pharmacokinetics to Assess IM Dosing and Early Drug Exposure for Status EpilepticusE Capparelli, K Chiswell, B Smith, D Siegel, S Weinstein, S Muchohi,  M Reed, J Barrett,  S de Wildt, E Jaqc-Aigrain, J Ma, T Glauser for the Pediatric Trials Network.
  • Poster Presentation: Tuesday, May 3 at 7:30 AM — Using Population Pharmacokinetics and Electronic Health Records to Assess Piperacillin Safety in Infants. S Salerno, C Hornik, M Cohen-Wolkowiez, PB Smith, R Clark, and D Gonzalez on behalf of the Administrative Core Committee of the Best Pharmaceuticals for Children Act – Pediatric Trials Network.

PTN Post: Issue 16 (March 2016)

Check out the Spring 2016 issue of the PTN Post, the newsletter for the Pediatrics Trials Network. This issue highlights the continuation of the Sildenafil Cohort 2 program, the new role of Child and Family Advocate, and PTN’s presentations at the upcoming Pediatric Academic Society meeting in Baltimore.

We hope you enjoy this issue, and as always, we welcome your comments and feedback.

NICHD Announces Research Funding Opportunity (U54)

Specialized Centers in Research in Pediatric Developmental Pharmacology (U54) 

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) announces the re-competition of the Research in Pediatric Developmental Pharmacology Centers Program (RPDP). 

The NICHD proposes to fund a limited number of research Centers that will provide an arena for multidisciplinary interactions between basic and clinical scientists interested in establishing high-quality translational research programs in the area of pediatric developmental pharmacology. The Centers also will serve as a national resource for the education of new scientists electing to pursue careers in the conduct of translational research in high priority areas of pediatric developmental pharmacology. Finally, Center investigators will facilitate important community outreach and education efforts to increase awareness and convey the importance and implications of their research activities to the general public.

Application deadline: February 18, 2016

Project babyTAPE Measures Up

babyTAPEOn December 18, 10 days ahead of schedule, the PTN babyTAPE team enrolled its 2,000th participant.

On January 29, the babyTAPE databse was locked.

The data collected in the babyTAPE study will be used to develop, design, and validate a weight estimation tool, similar to what is pictured, specific to infants.

The study is chaired by Dr. Susan Abdel-Rahman from Children’s Mercy Hospital in Kansas City, MO.  The PTN Program is chaired by Dr. Danny Benjamin and operationalized by Katherine Berezny (Program Manager at DCRI).

PTN Post: Issue 15 (December 2015)

Check out the Fall-Winter 2015 issue of the PTN Post, the newsletter for the Pediatrics Trials Network. This issue highlights four exciting PTN projects: timolol in infants with hemangiomas; anti-epileptics and pantoprazole for obese children; and furosemide for BPD. We hope you enjoy this issue and as always, we welcome your comments and feedback.

Timolol for Infantile Hemangiomas under Review

Since first reported in 2008 that propranolol, a beta blocker, was effective in the treatment of Infantile Hemangiomas (IH)—a birthmark that most commonly appears as a rubbery, bright red nodule of extra blood vessels in the skin, commonly called a “strawberry”—this class of drug has been used as the first line of therapy for infants with IH. Timolol, also a beta blocker, is available in topical formulation, and increasingly used off-label for small, non-complicated IH. The popularity of timolol is likely due to its perceived safety as a topical drug. However, data on timolol efficacy, safety and pharmacokinetics are limited.

Under the protocol thought leadership of Dr. Beth Drolet, Principal Investigator, the PTN’s Timolol study will enroll 100 infants between the ages of ≥32 to <50 weeks postmenstrual age. The infants will be treated with timolol for 28 days then randomized into 2 groups. One group will continue timolol treatment while the other will be withdrawn from treatment. Both groups will remain on the study in their respective groups for up to 120 days. The study will begin to enroll in the early summer of 2016 in approximately 10 US sites, and will end in the fall of 2017. The data received from the study will be presented to the FDA to support the use of timolol for the treatment of IH.